Rotaviruses are triple-layered particles that contain four major capsid proteins, VP2, VP4, VP6, and VP7, and two minor proteins, VP1 and VP3. We have cloned each of the rotavirus genes coding for a major capsid protein into the baculovirus expression system and expressed each protein in insect cells. Coexpression of different combinations of the rotavirus major structural proteins resulted in the formation of stable virus-like particles (VLPs). The coexpression of VP2 and VP6 alone or with VP4 resulted in the production of VP2/6 or VP2/4/6 VLPs, which were similar to double-layered rotavirus particles. Coexpression of VP2, VP6, and VP7, with or without VP4, produced triple-layered VP2/6/7 or VP2/4/6/7 VLPs, which were similar to native infectious rotavirus particles. The VLPs maintained the structural and functional characteristics of native particles, as determined by electron microscopic examination of the particles, the presence of nonneutralizing and neutralizing epitopes on VP4 and VP7, and hemagglutination activity of the VP2/4/6/7 VLPs. The production of VP2/4/6 particles indicated that VP4 interacts with VP6. Cell binding assays performed with each of the VLPs indicated that VP4 is the viral attachment protein. Chimeric particles containing VP7 from two different G serotypes also were obtained. The ability to express individual proteins or to coexpress different subsets of proteins provides a system with which to examine the interactions of the rotavirus structural proteins, the role of individual proteins in virus morphogenesis, and the feasibility of a subunit vaccine.
The importance of rotaviruses as etiologic agents of infantile diarrhea in humans and animals is now clearly established (15, 25) . The recognition that rotaviruses are the major cause of life-threatening diarrheal disease and of significant morbidity in young children has focused efforts on disease prevention and control against these viruses. Studies on rotavirus gene structure and function are helping these efforts. For example, the cloning and subsequent expression of individual protein products have helped to elucidate the function of each protein in virus structure, replication, and assembly (12, 34) . Analysis of the antigenic, functional, and molecular properties of expressed gene products, alone or in conjunction with other viral proteins, is allowing intrinsic properties of each gene product to be determined. Finally, the availability of large amounts of immunogenic structural proteins is facilitating vaccine testing and the production of inexpensive diagnostic tests.
The genome of rotaviruses consists of 11 segments of double-stranded RNA. The double-stranded RNA is enclosed in the viral capsid, which consists of three layers of proteins (12) . The rotavirus outer layer is composed of the glycoprotein VP7 and dimeric spikes of VP4 (12, 37, 42, 46) . Both outer capsid proteins induce neutralizing antibodies (6, 12, 22, 36) . VP4 is the viral hemagglutinin (24, 31) . The major capsid protein VP6, which comprises >80% of the protein mass of the particle, is located on the inner capsid and contains the subgroup antigen (15) . The presence of VP6 on virus particles has been associated with viral RNA polymerase activity (5) . Baculovirus-expressed VP6 spontaneously forms into the native trimeric conformation and can further assemble into Briefly, polyadenylated mRNA was cloned by using the cDNA Synthesis System Plus kit (Amersham International, Amersham, England). The synthesized cDNA was ligated into SmaI-cut, dephosphorylated pUC13 (gene 4) or into PstI- cleaved, dG-tailed pBR322 (gene 9). The 5' end of gene 4 was cloned by using an internal primer to extend the cDNA to the end of the gene, using SAl1 mRNA as the template. A second primer to the 5' end was annealed to the first strand of cDNA, and the second strand of cDNA was synthesized by using the Klenow fragment of DNA polymerase (Promega, Madison, Wis.). A full-length cDNA for gene 4 was obtained by ligation of two overlapping clones into pGEM 3Zf+ (Promega).
The gene segment 9, coding for a serotype Gl VP7 from a human rotavirus isolate (Houston 8697, 1991), was cloned by reverse transcription-PCR (1) . Briefly, the first-strand cDNA was synthesized by using a primer to the 3' end (GGTCACAT bpCATACAATTCTAATCTAAG) and reverse transcriptase. Double-stranded cDNA was synthesized by using a primer to the 5' end (GGCT11TAAAAGAGAGAATITCCGTCTGG) by PCR with Taq polymerase (Life Science Inc., St. Petersburg, Fla.). The double-stranded cDNA was cloned into the pCR 1000 vector (TA Cloning System; Invitrogen Co., San Diego, Calif.) and designated pCR1000/HRV8697/G9.
For construction of baculovirus recombinants, the fulllength SAl 1 gene 4 cDNA was subcloned by blunt-end ligation into the Klenow filled-in BamHI site of pVL941. The SAl gene 9 cDNA from bp 92 to the end of the SAl 1 gene segment was inserted into pVL941 by blunt-end ligation. This resulted in the utilization of the second in-phase initiation codon for the expression of VP7. The serotype Gl gene 9-containing plasmid, pCR1000/HRV8697/G9, was digested with NotI and SpeI and cloned into the NotI-XbaI sites of pVL1392. Baculovirus recombinants for SAl 1 genes 4 and 9 were obtained by calcium phosphate precipitation using wild-type baculovirus DNA and the rotavirus gene-containing baculovirus transfer vector as previously described (13) . The Characterization of VLPs. The VLPs were analyzed by polyacrylamide gel electrophoresis (PAGE), using a modification of the method of Laemmli with 12% separating and 4% stacking gels as previously described (32) . Samples were dissociated by boiling for 3 min in sample buffer containing 1% sodium dodecyl sulfate (SDS), 10% 2-mercaptoethanol, 0.5 M urea, 0.05 M Tris-HCl (pH 6.8), 10% glycerol, and 0.0025% phenol red. Radiolabeled proteins were monitored on gels following fluorography as previously described (32) . Western blot (immunoblot) analysis using a mouse hyperimmune serum prepared against triple-layered SAl1 virus was performed as previously described (6). The Western blots were scanned and analyzed on a UVP System 5000 gel documentation and analysis system (Ultra Violet Products, Science Park, Cambridge, England).
ELISA to analyze epitope integrity. The anti-VP7 monoclonal antibodies (MAbs) used in the enzyme-linked immunosorbent assay (ELISA) were two serotype G3 neutralizing MAbs, YO-1E2, kindly provided by K. Taniguchi (44) , and 159, and 60, a nonneutralizing MAb kindly provided by H. B. Greenberg (11) . The anti-VP4 MAbs used in the ELISA were two nonneutralizing MAbs, 3D8 and 5E4 (6), and 2G4, a neutralizing MAb, provided by H. B. Greenberg. Polyvinyl 96-well microtiter plates were coated with 100 RI (2 ,ug/ml) of highpressure liquid chromatography-purified MAb in carbonatebicarbonate buffer (pH 9.6). The plates were incubated overnight at room temperature and then were blocked with 200 RI of BLOTTO (5% [wt/vol] Carnation nonfat dry milk) per well for 2 h at 37°C and washed five times. All washes were performed with 0.01 M phosphate-buffered saline (PBS) containing 0.05% Tween 20 (Sigma Chemical Co., St. Louis, Mo.). The different types of VLPs or CsCl-purified triple-layered SAll were diluted 1:4 and 1:8 in 0.5% BLOTTO, then 50 ,lI was added to the blocked wells of the microtiter plates, and the mixtures were incubated for 2 h at 37°C. After the plates were washed five times, 50 ,lI of hyperimmune guinea pig antirotavirus serum was added to each well, and the plates were incubated for 2 h at 37°C. After an additional five washes, horseradish peroxidase-conjugated goat anti-guinea pig immunoglobulin G antibody (HyClone Laboratories, Logan, Utah) was added, and the plates were incubated for 1 h at 37°C. The plates were washed again five times, and ABTS [2,2'-azinobis(3-ethylbenzthiazoline sulfonic acid); Sigma) was added. After a 30-min incubation at room temperature, optical densities were determined at 414 nm with a Titertek Multiskan plate reader (Flow Laboratories, Inc., McLean, Va. (33).
Immunoelectron microscopy. The chimeric VLPs were labeled with MAb-gold probes. In this procedure, purified Gi and G3 MAbs were labeled with 5-and 15-nm colloidal gold AuroBeads (Amersham, Arlington Heights, Ill.), respectively, as described by the manufacturer. Briefly, AuroBeads (adjusted to pH 9) were mixed with the minimal protecting amount of the MAb (dialyzed against 2 mM borax buffer, pH 9). After the addition of BSA (1%, final concentration), the MAb-gold probe was pelleted, purified on a 10 to 30% glycerol gradient, and then dialyzed against 20 (14) .
RESULTS
Production of VLPs. The cDNA coding sequences for the SA1l gene segments 4 and 9 were cloned into the baculovirus transfer vector pVL941 or pVL1392 for the human rotavirus gene 9. Individual recombinants obtained, designated pVL941/ SA11-4, pVL941/SA11-9, and pVL1392/HRV8697-9, respectively, were tested and confirmed for their ability to produce VP4 and VP7 (see below). To produce VLPs, Sf9 cells were coinfected with different combinations of the baculovirus recombinants BacRf2A, pVL941/SA11-4, pAc461/SA11-6, and pVL941/SA11-9 or pVL1392/HRV8697-9. Particles were purified from the media of cells infected with the different combinations of recombinant baculoviruses and analyzed by EM.
Coexpression of BacRf2A and pAc461/SA11-6 resulted in the formation of VP2/6 particles (Fig. 1A) , which had structural features similar to those of double-layered virions (Fig. 1B) as previously described (26) . Coexpression of BacRf2A, pAc461/ SA11-6, and pVL941/SA11-4 resulted in the formation of VP2/4/6 particles (Fig. 1C) . Formation of these VP2/4/6 particles indicated that VP4 interacted directly with VP6 in the absence of the second outer capsid protein, VP7. Comparison of native double-layered rotavirus VP2/6 and VP2/4/6 particles by EM revealed similar structures indicating that the addition of VP4 to the VP2/4/6 particles does not perceptively change the structure or the diameter of these particles. The presence of VP4 on the VP2/4/6 particles was confirmed by both biochemical and biological studies (see below).
Coexpression of BacRf2A, pAc461/SA11-6, and pVL941/ SA11-9 and of BacRf2A, pVL941/SA11-4 pAc461/SA11-6, and pVL941/SA11-9 resulted in the formation of VP2/6/7 (Fig. 1D) and VP2/4/6/7 (Fig. 1E) particles, respectively, with structures similar to those of triple-layered virions (Fig. 1F ). VP2/6/7 and VP2/4/6/7 VLPs of the bovine Rf strain also were produced and had properties similar to those of the VLPs containing SA11 VP6 and VP7 (data not shown). VP2/4/6/7 VLPs containing VP7 from either serotype Gl, G3, or G6 showed no differences in negative-stain electron micrographs (data not shown). EM analysis of purified VP2/4/6/7 particles, stored at 4°C for at least 1 year, revealed that the particles remained intact and thus are very stable.
Composition of the recombinant VLPs. The different types of particles were analyzed by SDS-PAGE and Western blot analysis to confirm the presence of each of the structural proteins in the expressed particles. Comparison of the different 35S-labeled VLPs analyzed by SDS-PAGE ( Fig. 2A) or Western blotting (Fig. 2B) showed that each of the genes used to infect the insect cells was expressed and incorporated into each of the respective particle types.
The proteins in the VP2/4/6/7 and triple-layered SAl 1 particles were detected by Western blotting with a polyclonal antiserum made against triple-layered SAl 1 particles in hyperimmunized mice (Fig. 3) . In some preparations of VP2/4/6/7
VLPs, the detected VP4 migrated at the same position as uncleaved VP4 of authentic triple-layered SA 1 particles grown in the absence of trypsin (lanes 2 and 3) . In other preparations of VP2/4/6/7 VLPs, a protein which migrated with VP5*, a trypsin cleavage product of VP4, was detected (lanes 1 and 2) which migrated with VP5* from virus grown in the presence of trypsin (lane 4).
Although EM of these VLPs revealed that each preparation contained 90 to 95% triple-layered particles, variation was seen in the amount of the different proteins incorporated into the VLPs according to the method used for quantitation (data not shown). software package indicated the stoichiometry of proteins in VP2/4/6/7 VLPs was similar to that in particles analyzed simultaneously and probed with a polyclonal anti-SAI 1 serum. However, this quantitation is not precise, as the amount of VP2 detected in the VLPs is underestimated because the polyclonal antiserum made to SAl1 was used to detect the proteins and the expressed VP2 is from the Rf bovine strain of rotavirus. Also, Labbe et al. (27) reported that VP2 core-like particles purified in the absence of protease inhibitors contained a second VP2-specific polypeptide which migrated slightly lower than authentic VP2. Zeng et al. (47) MAbs used to capture the particles were 3D8 and 5E4, two nonneutralizing MAbs, and 2G4, a neutralizing MAb. All particles which contained VP7, i.e., native triple-layered SAl 1, and the VP2/6/7 and VP2/4/6/7 VLPs showed a positive reaction with the VP7 MAbs (Table 1) . Conversely, the particles which contained VP4, native triple-layered SA1l, and the VP2/4/6 and VP2/4/6/7 VLPs all showed a positive reaction with the VP4 MAbs. Therefore, the VLPs retained epitope integrity to each of the three VP4 and three VP7 MAbs used in the ELISA. We also determined if the different virus-like particles could hemagglutinate chicken RBCs. Chicken RBCs were hemagglutinated by triple-layered SAl 1 and the VP2/4/6/7 VLPs (Table  1) . In contrast, VP2/6, VP2/4/6, and VP2/6/7 VLPs did not hemagglutinate the chicken RBCs. Since VP4 has been shown to be the hemagglutinin and baculovirus-expressed VP4 alone has HA activity (data not shown) (31) , the lack of reactivity of VP2/4/6 particles to hemagglutinate chicken RBCs was unexpected. Several preparations of VP2/4/6 particles, which were shown to contain VP4 or VP5* by Western blotting, were screened for their HA ability; none of the preparations hemagglutinated chicken RBCs.
Antiserum produced in mice against the recombinant VP2/ 4/6/7 particles also detected the viral proteins VP2, VP4, VP6, and VP7 by Western blot analysis (Fig. 4) , although the amount of antibody produced to each protein differed for each mouse. These results confirmed that each of the proteins in the VLPs is antigenic.
Cell binding properties of the VLPs. We also used these different VLPs to address the question of which rotavirus protein is involved in cell binding. The VP2/4/6, VP2/4/6/7, and triple-layered particles were able to bind to MA104 cells (Fig.   5 ), whereas the VP2/6 and VP2/6/7 particles did not bind to MA104 cells. This result indicates that only those particles which contain VP4 bind to MA104 cells.
Characterization of the serotype Gl and G3 VLPs. To determine if chimeric particles could be obtained, VLPs were produced by coinfecting Sf9 cells with the baculovirus recombinants for genes 2, 4, and 6 and either the SAl 1 (G3) gene 9 or both the SAil (G3) and the HRV8697 (Gi) gene 9. These VLPs were characterized by using a MAb ELISA typing assay for VP7. The VLPs containing the G3 VP7 reacted with the MAb for serotype G3, and the VLPs containing the Gi and G3 YO-1E2   2  14  57  36  137  39  421  177  294  107  0  159  52  34  97  74  908  517  1,757  1,645  1,231  887  15  60  28  11  99  53  212  94  557  451  173  136  23   VP4  3D8  0  26  313  180  0  27  776  451  310  38  5  5E4  0  26  611  268  0  26  624  316  125  53  5  2G4  23  23  1,021  545  75  38  1,544  1,381  253 VP7s were positive with both G1 and G3 MAbs (data not shown). Antiserum produced to the VLPs containing the G3 or the G1 and G3 VP7s was assayed for the ability to neutralize either SAl (serotype G3) or Wa (serotype G1) ( Table 2) . Antiserum produced to the VLPs containing the G3 VP7 was able to neutralize SAl1 but not Wa. In contrast, antiserum to the VLPs containing the G1 and G3 VP7s was able to neutralize SAl1 and Wa, indicating that both VP7s were immunogenic and able to induce neutralizing antibodies.
KU-4-5-nm gold (serotype GI) or YO-lE2-15-nm gold (serotype G3) probes were used to determine if the VLPs made with both G1 and G3 VP7s contained both VP7s on a single particle. The KU-4-5-nm gold probe surrounded the VLPs containing the G1 VP7 (Fig. 6A) , and the YO-1E2-15-nm gold probe surrounded the VLPs containing the G3 VP7 (Fig. 6C) . In contrast, the KU-4-5-nm gold probe did not react with the VLPs containing the G3 VP7 (Fig. 6B) , and the YO-lE2-15-nm gold probe did not react with the VLPs containing the G1 VP7 (data not shown). The VLPs made with both G1 and G3 VP7s were surrounded by both gold probes used (Fig. 6D) , indicating that chimeric particles that contained VP7 from both serotypes G1 and G3 were produced. DISCUSSION The production of single or combinations of viral proteins in high yields from expression vector systems offers new ways to study viral protein functions in virus structure, replication, and DPV   1  3  2  <50  <50  <50  800  2  3  2  <50  <50  <50  1,600  3  3  2  <50  <50  <50  1,600   1  1 and 3  5  <50  100  <50 6,400  2  1 and 3  5  <50  100  <50  6,400  3  1 and 3  5  <50  200  <50  3,200 " Serum neutralizing antibody response in mice immunized with serotype G3
or GI and G3 VLPs, using Freund's adjuvant. Plaque reduction neutralization assays were performed against Wa and SAl 1. assembly. Redmond (39) reported that spherical particles which resembled smooth, double-shelled rotavirus could be assembled from baculovirus recombinants expressing the bovine rotavirus strain C486 VP6 and VP7. Our experience in coexpressing SAI 1 VP6 and VP7 in insect cells or mixing these proteins in vitro confirmed that VP6/VP7 particle-like structures can be formed but that these structures are heterogeneous and not stable (data not shown). In contrast, use of VP2 as a scaffolding protein permitted VLPs of different protein compositions (i.e., VP2/6, VP2/4/6, VP2/6/7, and VP2/4/6/7) to be formed by the expression of different combinations of VP2, VP4, VP6, and VP7. The recombinant VLPs were harvested from the media or cells 5 days postinfection, and they shared many similarities to native rotavirus particles, including the ability to be processed by routine purification procedures, excellent stability, and similar structural features. The VP2/6/7 and VP2/4/6/7 particles are 90 to 95% complete double-layered and triple-layered particles, respectively, as estimated by negative-stain EM, and VP2/4/6/7 particles stored at 4°C for at least 1 year remained intact by EM and biochemical criteria.
Western blot analysis revealed that different preparations may contain VP4, VP5*, or a mixture of VP4 and VP5*. It has not been determined when the cleavage event of VP4 occurs, whether particles are formed with a full-length VP4 which subsequently is cleaved, or if particles can be formed following insertion of a cleaved VP4. However, this specific cleavage probably occurs after VP4 is inserted in the VLP because it probably requires the dimeric conformation of the VP4 spike. Since the VLP particles with VP5* were not produced in the presence of trypsin, endogenous proteases from the media or cells must be responsible for this cleavage. This hypothesis is consistent with the observation that VLPs containing fulllength VP4 can be obtained from Sf9 cells coinfected and maintained in media containing serine protease inhibitors (data not shown).
Several previous studies have sought to determine which rotavirus protein mediates rotavirus attachment to cell surfaces. Initial studies which examined binding of metabolically radiolabeled soluble viral proteins to cell monolayers identified VP7 to be the rotavirus protein which binds specifically to MA104 cells (19, 41 (2) . Finally, we also have shown that chimeric VLPs containing either serotype Gi or G3 VP7s or VLPs which contained both Gi and G3 VP7s can be obtained. This finding was not unexpected since we are able to use the Rf bovine VP2 as a scaffolding protein on which to build the VP6 and the VP7 and VP4 layers and reassortants containing the outer capsid proteins from different serotypes can be obtained during replication in mammalian cells (8) . In addition, others have suggested that mosaic capsids containing two different VP7 specificities can be formed in cells infected with two viruses of different serotype specificity (45) . However, it was not confirmed that VLPs containing the outer capsid protein from different serotypes could be made from coexpression of proteins in the absence of active rotavirus replication. Our ability to use individual baculovirus recombinants to form particles allows VLPs composed of VP2/6 and either or both VP4 and VP7 from different P and G types to be formed and evaluated as subunit vaccines and also to determine the role that VP4 or VP7 alone plays in neutralization and protection. Our results also suggest that a polyclonal serum to VP2/4/6 particles containing different P types can be prepared, and this may aid in the development of P-typing reagents.
These results add to an increasing literature on the success of producing VLPs by using baculovirus (7, 21, 23, 26) . Thus, rotavirus VLPs exemplify complex particle formation with some similarities to orbiviruses (28, 30) .
